Bavarian Nordic — November 2021
-
Det med opjustering, er naturligvis et gæt - helt uden begrundelse
-
Zea - Tak. Når jeg kigger på Q1 og Q2.... så modtog jeg rapportering kl. 10.00 (?)
-
Selvtak. Min computer har muligvis probs med tidszonen disse dage og min hukommelse svigter
-
ZP: det kommer altid ifm at amerikanerne har fået børstet tænder i cola og er klar:)
-
Nogle forventninger til Zegalogue salget? Xeris Pharma har til sammenligning solgt Gvoke hypopen for $11M, svarende til 71MDKK i Q3. Men de har naturligvis også haft produktet på markedet i over et år nu
-
Jeg håber dog på en stærk start, da august/september skulle have høj TRx volume, ifølge ZP selv pga. "back to school seasonality" - https://static1.squarespace.com/static/58983777d1758e28995640b4/t/615cba3691ed4149ae73eabd/1633466938779/Zealand+Pharma+Corporate+Presentation_October.pdf side 12
-
Eli Lillys Baqimi solgte for $31.9M/206MDKK i Q3
-
Baqsimi*
-
Man må også forvente, at den forholdsvist store salgsstyrke som ZP har fået etableret ifm. Valeritas købet bør kunne sælge en fin mængde
i højsæson -
(Kort video).
Ugekommentar - Regnskaber fra Genmab og Ambu. Der er kommet flere regnskaber, og i denne uge omtaler Helge Larsen Vestas, Genmab, Bavarian, Ambu, Tesla og Teva. https://www.proinvestor.com/index.php?p=debat_1&postid=98475 -
-
Financial results for the first nine months of 2021
• Revenue: DKK 238.6 million / USD 37.1 million (DKK 290.0 million / USD 45.6 million in the first nine months of 2020).
• Net operating expenses: DKK -906.2 million / USD -141.1 million (DKK -714.5 million / USD -112.3 million in the first nine months of 2020). -
• Net operating result: DKK -762.6 million / USD -118.8 million (DKK -449.1 million / USD -70.6 million in the first nine months of 2020).
• Cash, cash equivalents, and marketable securities: DKK 1,049.0 million / USD 163.3 million as of September 30, 2021 (September 30, 2020: DKK 1,528.6 million / USD 240.4 million). -
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies
Company announcement – No. 67/ 2021 Interim report for 9M 2021 Zealand Pharma Presents Financial Results for the First Nine Months of 2021;...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind